domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -85,10 +85,16 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu
 
 
 ### Additional Evidence (challenge)
-*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-18*
+*Source: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination | Added: 2026-03-18*
 
 WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
+
+Medicare-specific modeling shows $715M net savings over 10 years when comprehensive semaglutide access includes T2D, obesity, and MASH indications. T2D-related savings ($892M) exceed obesity-related costs ($205M), with 38,950 CV events and 6,180 deaths avoided. This challenges the universal 'inflationary through 2035' framing by demonstrating that risk-bearing payers capturing both drug costs and downstream savings can achieve net cost reduction.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -50,10 +50,16 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
 
 Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
+
+Medicare modeling quantifies multi-organ protection value: per 100,000 subjects treated, semaglutide prevents 2,791 non-fatal MIs, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths. Per-subject savings breakdown: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Total 10-year impact: 38,950 CV events avoided, 6,180 deaths prevented.
+
 ---
 
 Relevant Notes:

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -36,10 +36,16 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
 
 
 ### Additional Evidence (confirm)
-*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
 
 SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
+
+Medicare modeling confirms CKD cost savings at $2,074 per subject treated over lifetime, contributing to overall $715M net savings when combined with T2D ($14,431/subject) and CV ($1,512/subject) benefits. CKD savings are smaller than T2D but still material to the comprehensive value calculation.
+
 ---
 
 Relevant Notes:

domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md

@@ -33,10 +33,16 @@ The composition of spending shifts dramatically: less on chronic disease managem
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-23-cbo-medicare-trust-fund-2040-insolvency]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2026-02-23-cbo-medicare-trust-fund-2040-insolvency | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
 (extend) The Medicare trust fund fiscal pressure adds a constraint layer to the cost curve dynamics. While new capabilities create upward cost pressure through expanded treatment populations, the trust fund exhaustion timeline (now 2040, accelerated from 2055 by tax policy changes) creates a hard fiscal boundary. The convergence of demographic pressure (working-age to 65+ ratio declining to 2.2:1 by 2055), MA overpayments ($1.2T/decade), and reduced tax revenues means automatic 8-10% benefit cuts starting 2040 unless structural reforms occur. This fiscal ceiling will force coverage and payment decisions in the 2030s independent of technology trajectories, potentially constraining the cost curve expansion that new capabilities would otherwise enable.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
+
+Medicare semaglutide modeling reveals a boundary condition: when a single risk-bearing payer captures both treatment costs and downstream savings, comprehensive prevention can be cost-saving ($715M over 10 years) even as system-level spending increases. This suggests the 'cost curve bends up' claim applies to fragmented payment systems but not to integrated risk-bearing entities like Medicare or capitated MA plans.
+
 ---
 
 Relevant Notes:

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -49,16 +49,22 @@ The BALANCE Model moves payment toward genuine risk by adjusting capitated rates
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
 
 CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-01-01-nashp-chw-state-policies-2024-2025]] | Added: 2026-03-18*
+*Source: 2025-01-01-nashp-chw-state-policies-2024-2025 | Added: 2026-03-18*
 
 CHW reimbursement infrastructure demonstrates the same payment boundary stall in the SDOH domain: 20 states with approved SPAs after 17 years, with billing code uptake remaining slow even where reimbursement is technically available. The bottleneck is not policy approval but operational infrastructure — CBOs cannot contract with healthcare entities, transportation costs are not covered, and 'community care hubs' are emerging as coordination infrastructure. This parallels VBC's 60% touch / 14% risk gap: technical capability exists but the operational infrastructure to execute at scale does not.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
+
+Medicare semaglutide modeling demonstrates why full-risk bearing matters: comprehensive access saves $715M over 10 years because Medicare captures both drug costs and downstream savings from prevented T2D, CKD, and CV complications. This economic inversion only works when a single payer bears both costs and savings—fragmented fee-for-service breaks the link, with one entity paying for prevention and different entities capturing long-term savings.
+
 ---
 
 Relevant Notes:

inbox/queue/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "comprehensive-semaglutide-access-saves-medicare-through-multi-indication-cardiovascular-and-metabolic-benefits-when-single-payer-bears-both-costs-and-savings.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "comprehensive-semaglutide-access-saves-medicare-through-multi-indication-cardiovascular-and-metabolic-benefits-when-single-payer-bears-both-costs-and-savings.md:set_created:2026-03-18"
+    ],
+    "rejections": [
+      "comprehensive-semaglutide-access-saves-medicare-through-multi-indication-cardiovascular-and-metabolic-benefits-when-single-payer-bears-both-costs-and-savings.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-18"
+}

inbox/queue/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md

@@ -7,9 +7,13 @@ date: 2025-06-01
 domain: health
 secondary_domains: [internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
+processed_by: vida
+processed_date: 2026-03-18
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,13 @@ Key findings:
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
 EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
+
+
+## Key Facts
+- Medicare semaglutide modeling projects $715M net savings over 10 years (range: $412M to $1.04B)
+- T2D-related impact: $892M savings; Obesity-related impact: $205M costs; MASH-related impact: $28M savings
+- 38,950 cardiovascular events avoided over 10 years
+- 6,180 deaths avoided (CV events + CKD/MASH progression)
+- Per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
+- Average per-subject lifetime treatment costs: $47,353
+- Per-subject savings: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events